Neurológia pre prax 5/2021
Ocrelizumab – clinical evaluation and disease progression – 6,5 years data
The treatment of multiple sclerosis has undergone great progress in recent years. With the advent of new drugs, our therapeutic possibilities are expanding. The therapeutic goal remains the stability of the disease, which is monitored in clinical practice by controlling the signs of attack or disease progression. This article discusses new data on clinical activity and effects on disease progression in patients treated with ocrelizumab.
Keywords: multiple sclerosis, ocrelizumab, ARR, CDP
